|Tested species reactivity||Human, Mouse, Non-human primate, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic non-phosphopeptide derived from human MARK1/2/3/4 around the phosphorylation site of Thr215 (L-D-TP-F-C)|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 50% glycerol, 150mM NaCl|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MARK1 (MAP/microtubule affinity-regulating kinase 1) belongs to the MARK family of serine/threonine kinases. MARK family protein kinases phosphorylate microtubule-associated proteins and may play a role in cytoskeletal stability. MARK2 refers to MAP/microtubule affinity-regulating kinase 2 isoform a [Homo sapiens]. EMK (ELKL Motif Kinase) is a small family of ser/thr protein kinases involved in the control of cell polarity, microtubule stability and cancer. Several cDNA clones have been isolated that encoded two isoforms of the human ser/thr protein kinase EMK1 called MARK2. MARK3 was originally identified as a marker that was induced by treatment with DNA damaging agents, and loss of MARK3 was found with carcinogenesis in the pancreas. MARK4 contains an N terminal serine/threonine kinase domain, a central ubiquitin associated domain, and a C terminal KA1 associated kinase domain. RT PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.